SOUTH SAN FRANCISCO, Calif.,
May 31, 2018 /PRNewswire/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that
Raul Rodriguez, the company's
president and chief executive officer, is scheduled to present a
company overview at the Jefferies Global Healthcare Conference in
New York City on Tuesday, June 5, 2018 at 10:30am EDT.
To access the live webcast of the presentation or the subsequent
archived recording, log on to www.rigel.com. Please connect to
Rigel's website several minutes prior to the start of the live
webcast to ensure adequate time for any software download that may
be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with immune and
hematologic disorders, cancer and rare diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is
TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen
tyrosine kinase (SYK) inhibitor, for the treatment of adult
patients with chronic immune thrombocytopenia who have had an
insufficient response to a previous treatment. Rigel's current
clinical programs include Phase 2 studies of fostamatinib in
autoimmune hemolytic anemia and IgA nephropathy. In addition, Rigel
has product candidates in development with partners BerGenBio
AS, Daiichi Sankyo, and Aclaris Therapeutics.
Please see www.TAVALISSE.com for full Prescribing
Information.
Contact: Raul Rodriguez
Phone: 650.624.1302
Email: ir@rigel.com
Media Contact: Jessica Daitch
Phone: 917.816.6712
Email: jessica.daitch@syneoshealth.com
Logo -
https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg
View original content with
multimedia:http://www.prnewswire.com/news-releases/rigel-to-present-at-jefferies-2018-global-healthcare-conference-300657013.html
SOURCE Rigel Pharmaceuticals, Inc.